

Attn: Examiner Lucas

**Certificate of Transmission under 37 CFR 1.8**  
**Fax: (703) 746-8480**

I hereby certify that this correspondence is being facsimile transmitted  
to the United States Patent and Trademark Office.

on April 25, 2003.  
Date

Sloan Hobbs  
Signature

Sloan Hobbs  
Typed or printed name of person signing

Attorney's Docket No. 5470-238

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: MacDonald et al.  
Serial No.: 09/288,837  
Filed: April 8, 1999  
For: **METHODS AND MODIFIED CELLS FOR THE TREATMENT OF  
CANCER**

Art Unit: 1648  
Examiner: Z. Lucas

**Submission of:**

1. **Supplemental Amendment in response to Office Action of  
October 22, 2002 and Telephone Interview of April 16, 2003**
2. **Amendment Transmittal**
3. **Velders et al.**
4. **Gardner et al.**

(Number of Pages: 14 + Certificate of Transmission)

#3/  
Suppl. Amtd. G  
4.29.03

Attorney's Docket No. 5470-238

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: MacDonald et al.

Art Unit: 1648

Serial No.: 09/288,837

Examiner Z. Lucas

Filed: April 8, 1999

For: *METHODS AND MODIFIED CELLS**FOR THE TREATMENT OF CANCER*

April 25, 2003

Commissioner for Patents

Washington, DC 20231

Sir:

Transmitted herewith is an AMENDMENT in the above-identified patent application.

☒ Applicant claims small entity status. See 37 CFR §1.27.☒ No additional fee is required.☐ Other:

The fee has been calculated as shown below:

(COL. 1)		(COL. 2)	(COL. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	Claims Remaining After Amendment	Highest Number Previously Paid For	Present Extra	RATE	ADDIT. FEE	OR RATE	ADDIT. FEE
Total	* 18-	** 89	= 0	x 09=	\$ 0.00	x 18=	\$0.00
Indep	* 6-	*** 10	= 0	x 42=	\$ 0.00	x 84=	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+140=	\$	+280=	\$
				Total Add. Fee	\$0.00	OR Total	\$0.00

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

In re: MacDonald et al.  
Serial No.: 09/288,837  
Filed: April 8, 1999  
Page 2 of 2

- ☐ Please charge my Deposit Account No. 50-0220 in the amount of \$0
- ☐ A check in the amount of \$0.00 is enclosed to cover the fee.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0220.
- ☒ Any additional filing fees required under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,

  
Karen A. Magri  
Registration No. 41,965

Customer Number




20792

PATENT TRADEMARK OFFICE

**Certificate of Transmission under 37 CFR 1.8**

Fax: (703) 746-8480

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 25, 2003.

  
Sloan Hobbs

Attorney's Dock t No. 5470-238

PATENT#31  
Suppl.  
Amend. #4  
4.29.03  
✓

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: MacDonald et al.

Art Unit: 1648

Serial No.: 09/288,837

Examiner: Z. Lucas

Filed: April 8, 1999

For: *METHODS AND MODIFIED CELLS  
FOR THE TREATMENT OF CANCER*

April 25, 2003

Commissioner for Patents  
Washington, DC 20231

Sir:

**Supplemental Amendment**

Responsive to the Office Action dated October 22, 2002, and the telephone interview of April 16, 2003, it is respectfully requested that this application be reconsidered in view of the supplemental amendments and remarks set forth below. A first Amendment was submitted on February 24, 2003.

**In the Claims.**

Please replace the pending claims of like number with the following rewritten claims:

84. (Amended five times) A composition comprising infectious alphavirus particles in an immunogenically effective amount to prevent or treat cancer, wherein said alphavirus particles comprise one or more heterologous nucleotide sequences encoding a naturally occurring cancer cell antigen; and wherein said alphavirus particles infect antigen-presenting cells, and further wherein said alphavirus particles comprise one or more attenuating mutations.

91. (Amended) The composition of Claim 84, wherein said naturally occurring cancer antigen is selected from the group consisting of a helper T cell epitope, a cytotoxic T cell epitope, a T-dependent B cell epitope, and a T-independent B cell epitope.